Tucidinostat
- Generic Name
- Tucidinostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19FN4O2
- CAS Number
- 1616493-44-7
- Unique Ingredient Identifier
- 87CIC980Y0
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs
- First Posted Date
- 2021-09-27
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- United BioPharma
- Target Recruit Count
- 11
- Registration Number
- NCT05056974
- Locations
- 🇨🇳
Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan, Taiwan
Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Liaoning Tumor Hospital & Institute
- Target Recruit Count
- 82
- Registration Number
- NCT05047848
- Locations
- 🇨🇳
Liangning Tumor Hospital &Institute, Shenyang, Liaoning, China
Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH
- Conditions
- Interventions
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 37
- Registration Number
- NCT05008666
- Locations
- 🇨🇳
Department of Medical Oncology,Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2021-08-11
- Lead Sponsor
- Guangdong Women and Children Hospital
- Target Recruit Count
- 73
- Registration Number
- NCT04999540
Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 30
- Registration Number
- NCT04994210
- Locations
- 🇨🇳
SunYat-sen university cancer center, Guangzhou, China
Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 83
- Registration Number
- NCT04831710
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 48
- Registration Number
- NCT04724239
- Locations
- 🇨🇳
Cancer center of Sun Yat-sen University, Guangzhou, Guangdong, China
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL
- Conditions
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 190
- Registration Number
- NCT04668690
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- oubai
- Target Recruit Count
- 20
- Registration Number
- NCT04661943
- Locations
- 🇨🇳
The First Bethune Hospital of Jilin University, Changchun, Jilin, China
Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 45
- Registration Number
- NCT04562311
- Locations
- 🇨🇳
Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.